Clinical Characteristics of COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
- Enrollment
- 21
- Locations
- 15
- Primary Endpoint
- All-cause mortality of COVID-19 patients with liver cirrhosis
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
Detailed Description
Coronavirus disease 2019 (COVID-19) pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
Investigators
Xiaolong Qi
Chief, Institute of Portal Hypertension
Hepatopancreatobiliary Surgery Institute of Gansu Province
Eligibility Criteria
Inclusion Criteria
- •Aged 18 or above;
- •Laboratory-confirmed COVID-19 infection;
- •Pre-existing liver cirrhosis based on liver biopsy or clinical findings.
Exclusion Criteria
- •Pregnancy or unknown pregnancy status.
Outcomes
Primary Outcomes
All-cause mortality of COVID-19 patients with liver cirrhosis
Time Frame: From illness onset of COVID-19 to death from any cause, up to 365 days
7-day, 28-day, 60-day, 180-day and 365-day all-cause mortality of COVID-19 patients with liver cirrhosis
Secondary Outcomes
- Liver-related mortality of COVID-19 patients with liver cirrhosis(From illness onset of COVID-19 to death from liver-related cause, up to 365 days)
- Baseline characteristics of COVID-19 patients with liver cirrhosis(1 Day)
- Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis(From hospital admission to death, up to 365 days)